Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453916 | 1.00 | MEN1 (0.50) | MEN1USP2ALDH1A1MAPTKMT2A | |
| Aspartic Acid SCHEMBL8594964 | 0.94 | MEN1 (0.45) | MEN1USP2ALDH1A1MAPTKMT2A | |
| SCHEMBL1374079 | 0.88 | DPP7 (0.44) | MEN1USP2ALDH1A1MAPTKMT2A | |
| SCHEMBL3229876 | 0.85 | RRM1 (0.46) | ALDH1A1DPP7RRM1GNAI3GNAO1 | |
| SCHEMBL8230008 | 0.83 | MEN1 (0.50) | MEN1USP2ALDH1A1MAPTKMT2A | |
| SCHEMBL453917 | 0.83 | MEN1 (0.50) | MEN1USP2ALDH1A1MAPTKMT2A | |
| SCHEMBL2806338 | 0.83 | ECE1 (0.51) | DPP7ECE1 | |
| SCHEMBL4759296 | 0.83 | DPP7 (0.44) | DPP7RRM1ECE1LTA4HGNAI3 | |
| SCHEMBL3261069 | 0.82 | DPP7 (0.50) | USP2DPP7TSHRRRM1ECE1 | |
| SCHEMBL9374114 | 0.82 | DPP7 (0.38) | DPP7RRM1ECE1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173080-A1 | COMPOSITION OF IMMUNOMODULATING SERPIN, SERP-1 | SERPASS BIOLOGICS, INC. | 2023-06-08 | — | — | US | claimed |
| EP-4143222-A2 | COMPOSITION OF IMMUNOMODULATING SERPIN, SERP-1 | Arizona Board of Regents on behalf of Arizona State University (US) | 2023-03-08 | — | — | EP | claimed |
| US-20220275041-A1 | MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES | EXALT THERAPEUTICS, LLC | 2022-09-01 | — | — | US | claimed |
| CN-103083681-A | Drug for treating tumors and application thereof | UNIV TSINGHUA | 2013-05-08 | — | — | CN | claimed |
| CN-101596320-A | A kind of medicine and application thereof for the treatment of tumor | UNIV TSINGHUA (CN) | 2009-12-09 | — | — | CN | claimed |
| CN-101002946-A | Medicine for treating tumor and application thereof | UNIV TSINGHUA (CN) | 2007-07-25 | — | — | CN | claimed |
| EP-0788375-A3 | — | OFFORD ROBIN EWART | 1997-09-17 | — | — | EP | claimed |
| EP-0788375-A2 | FUNCTIONALIZED POLYMERS FOR SITE-SPECIFIC ATTACHMENT | Offord, Robin Ewart (CH) | 1997-08-13 | — | — | EP | claimed |
| WO-1996041813-A9 | FUNCTIONALIZED POLYMERS FOR SITE-SPECIFIC ATTACHMENT | — | 1997-06-19 | — | — | WO | claimed |
| WO-1996041813-A2 | FUNCTIONALIZED POLYMERS FOR SITE-SPECIFIC ATTACHMENT | OFFORD ROBIN E (CH) | 1996-12-27 | — | — | WO | claimed |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4104853-B1 | ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT | POLARIS GROUP (KY) | 2026-05-06 | — | — | EP | disclosed |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | ELANCO US INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260091083-A1 | CYCLIC PROSAPOSIN PEPTIDES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260091079-A1 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-04-02 | — | — | US | disclosed |
| WO-1996041813-A2 | FUNCTIONALIZED POLYMERS FOR SITE-SPECIFIC ATTACHMENT | OFFORD ROBIN E (CH) | 1996-12-27 | — | — | WO | disclosed |
| WO-1995034673-A1 | PROCESS FOR PRODUCING POLYVALENT AND PHYSIOLOGICALLY DEGRADABLE CARBOHYDRATE RECEPTOR BLOCKERS BY ENZYMATIC GLYCOSYLATION REACTIONS, AND USES THEREOF FOR MANUFACTURING CARBOHYDRATE COMPONENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-21 | — | — | WO | disclosed |
| EP-0539167-A2 | Peg imidates and protein derivatives thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| EP-0458079-A2 | Ultrasonic contrast agent, its preparation and application as diagnostic or therapeutic | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-27 | — | — | EP | disclosed |
| EP-0383170-A2 | Methotrexate linked to polymers, process for their preparation, and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275041-A1 | MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES | IFNG, IRF3, IFNAR1 | MEN1 2902/4885USP2 2058/4885ALDH1A1 4826/4885 |
| US-20260091079-A1 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF | PSAP, VEGFA, ENPEP | MEN1 3502/4885USP2 526/4885ALDH1A1 4740/4885 |
| US-20260091083-A1 | CYCLIC PROSAPOSIN PEPTIDES AND USES THEREOF | PSAP, VIP, IAPP | MEN1 578/4885USP2 551/4885ALDH1A1 4779/4885 |
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DMPK, KRTCAP2 | MEN1 4217/4885USP2 4619/4885ALDH1A1 4401/4885 |
| US-12612440-B2 | Modified bovine G-CSF polypeptides and their uses | AARS1, NPEPPS, GLUL | MEN1 4354/4885USP2 2022/4885ALDH1A1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.